| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.01 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.074 | 0.01 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |